Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAGE: Ocrelizumab in Rheumatoid Arthritis
NCT00406419Phase 3Terminated
- Sponsor
- Genentech
- Start
- Dec 2006
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ocrelizumab in rheumatoid arthritis (RA), sponsored by Genentech. Started Dec 2006; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00406419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406419.